Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
4(80%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
2
40%
Ph phase_2
1
20%
Ph phase_3
1
20%

Phase Distribution

2

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

5

all time

Status Distribution
Active(4)
Completed(1)

Detailed Status

Recruiting4
Completed1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
4
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (50.0%)
Phase 21 (25.0%)
Phase 31 (25.0%)

Trials by Status

recruiting480%
completed120%

Recent Activity

4 active trials
Showing 5 of 5
recruitingphase_1

R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

NCT06594640
recruiting

Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil

NCT05959720
recruitingphase_1

Phase Ib Study of Rocbrutinib in Combination with R-CHOP in Patients with Newly Diagnosed B-cell Non-Hodgkin Lymphoma

NCT06251180
recruitingphase_3

Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5

NCT06284122
completedphase_2

Multicentre Study to Determine the Cardiotoxicity of R-CHOP Compared to R-COMP in Patients With Diffuse Large B-Cell Lymphoma

NCT00575406

Clinical Trials (5)

Showing 5 of 5 trials
NCT06594640Phase 1

R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

Recruiting
NCT05959720

Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil

Recruiting
NCT06251180Phase 1

Phase Ib Study of Rocbrutinib in Combination with R-CHOP in Patients with Newly Diagnosed B-cell Non-Hodgkin Lymphoma

Recruiting
NCT06284122Phase 3

Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5

Recruiting
NCT00575406Phase 2

Multicentre Study to Determine the Cardiotoxicity of R-CHOP Compared to R-COMP in Patients With Diffuse Large B-Cell Lymphoma

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5